$1.930
+0.301 (+15.57%)Al cierre
Noticias de RNXT
Eventos de RNXT
RenovoRx Publishes TIGeR-PaC Trial Data
RenovoRx announced the publication of pharmacokinetic and pharmacodynamic data from a sub-study of its ongoing Phase III TIGeR-PaC clinical trial in the journal Cancer Chemotherapy and Pharmacology. The data shows that TAMP-mediated delivery concentrated chemotherapy at the tumor site, extracting roughly 51% of the drug locally before it entered the bloodstream, meaningfully lowering systemic exposure in a way that could reduce systemic side effects. In addition, a statistically significant correlation between the drug's local metabolism and a drop in the CA 19-9 tumor marker provided an early indication of improved drug penetration into the tumor area and potential tumor response with intra-arterial delivery. RenovoRx also recently announced the closing of enrollment of the TIGeR-PaC trial, with trial completion expected in the first half of 2027 and expected initial top line data availability in the second half of 2027. IAG resulted in significantly lower total systemic gemcitabine exposure compared to IVG, despite being administered at a 50% higher infusion concentration rate, supporting the potential of TAMP to concentrate therapy at the intended treatment site while limiting systemic exposure. A targeted extraction ratio of 0.511 was observed, indicating approximately 51% of the intra-arterially delivered gemcitabine was extracted at the site of intra-arterial delivery before entering systemic circulation. This finding provides direct pharmacokinetic evidence supporting the targeted drug-delivery mechanism underlying the TAMP platform. A statistically significant correlation was observed between higher systemic levels of dFdU and greater reductions in CA 19-9 tumor marker levels following IAG treatment. dFdU is gemcitabine's inactive metabolite, and higher dFdU levels are consistent with rapid local uptake and metabolism of gemcitabine at the treatment site, providing an initial pharmacodynamic signal linking drug exposure with a biomarker of tumor response. No statistically significant differences in gemcitabine or dFdU pharmacokinetic parameters were observed based on IAG delivery site, whether administered via the superior mesenteric artery or the celiac artery. The Company believes this data provides evidence that IAG delivery via the TAMP therapy platform achieves meaningful local drug extraction while reducing systemic gemcitabine exposure.
RenovoRx Receives Patent Allowance for Cancer Treatment
RenovoRx announced that the U.S. Patent and Trademark Office has issued a notice of allowance for the company's patent application titled "Methods and Apparatuses for Delivery of Therapeutic Materials for the Treatment of Cancer." The newly allowed application provides additional patent protection for RenovoCath.
RenovoRx Raises 2026 Revenue Guidance to $3.75M-$4.25M
Consensus $3.21M. The company said, "RenovoRx is raising and tightening the range of its full-year 2026 revenue guidance to a range of $3.75 million to $4.25 million, from its prior range of $3.0 million to $4.0 million. The updated guidance implies year-over-year revenue growth of approximately 241% to 286% compared to full-year 2025 revenue of $1.1 million."
RenovoRx Reports Q2 Revenue of $909,000, Beating Expectations
Reports Q2 revenue $909,000, consensus $703,750. "In the second quarter of 2026, we delivered record revenue and executed on all three of the milestones we set for the business: revenue growth with another record revenue quarter, commercial momentum evidenced by several cancer center activations, and expansion of the application of our technology beyond locally advanced pancreatic cancer (LAPC)," said Shaun Bagai, Chief Executive Officer of RenovoRx. "We generated quarterly revenue of $909,000, an increase of approximately 61% compared to the first quarter of 2026, and approximately 115% compared to the second quarter of 2025. Our strong first half performance gives us confidence that our second half revenue will exceed our original full year forecast. This outlook is driven by more active commercial cancer center customers, more patients treated via procedures with RenovoCath, and repeat ordering across our existing customer base."
RenovoRx Completes Enrollment in Phase III TIGeR-PaC Trial
RenovoRx announced completion of enrollment in the company's Phase III TIGeR-PaC trial in locally advanced pancreatic cancer. As of August 7, TIGeR-PaC trial investigators have been notified by RenovoRx that patient enrollment is closing. Completion of the trial is expected during the first half of 2027, after 86 events have been observed. As of August 11, 78 events have occurred. Following completion of the trial, initial top line trial data is expected to be available during the second half of 2027.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.